ACADIA Pharmaceuticals Inc. (ACAD) Revenue, Earnings & Financial Statements
$18.32NASDAQ: ACADMarket Cap $3.17B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
ACADIA Pharmaceuticals Inc. most recently reported annual revenue of $1.1B, net profit of $391.0M. Revenue grew at an average annual rate of 19.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
ACADIA Pharmaceuticals Inc.: Revenue rose from $17.0M in 2016 to $1.1B in 2025, a change of +6205.9% over 9 years; net profit was positive in 2 of 10 reported years; operating margin moved from -1574.1% to 9.8%, a shift of +1583.9 percentage points; the most recent year shows net profit of $391.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$17.0M
$125.0M
$224.0M
$339.0M
$442.0M
$484.0M
$517.0M
$726.0M
$958.0M
$1.1B
Operating Expenses
$290.0M
$417.0M
$471.0M
$586.0M
$728.0M
$655.0M
$741.0M
$800.0M
$727.0M
$967.0M
Operating Profit
−$273.0M
−$292.0M
−$247.0M
−$247.0M
−$287.0M
−$170.0M
−$224.0M
−$73.0M
$231.0M
$105.0M
Operating Margin
-1574.1%
-234.1%
-110.6%
-72.7%
-64.9%
-35.2%
-43.2%
-10.1%
24.1%
9.8%
Other Income
$3.0M
$4.0M
$4.0M
$12.0M
$6.0M
$3.0M
$10.0M
$22.0M
$27.0M
$34.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$2.0M
$3.0M
$3.0M
$3.0M
$3.0M
$3.0M
$2.0M
$6.0M
$16.0M
$12.0M
Profit Before Tax
−$270.0M
−$288.0M
−$244.0M
−$234.0M
−$281.0M
−$168.0M
−$213.0M
−$51.0M
$258.0M
$139.0M
Tax rate (%)
-0.5%
-0.4%
-0.5%
-0.4%
-0.2%
-0.2%
-1.2%
-20.1%
12.3%
-181.5%
Net Profit
−$271.0M
−$289.0M
−$245.0M
−$235.0M
−$282.0M
−$168.0M
−$216.0M
−$61.0M
$226.0M
$391.0M
EPS
−$2.34
−$2.36
−$1.94
−$1.60
−$1.79
−$1.05
−$1.34
−$0.37
$1.36
$2.29
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$231.0M
$206.0M
$242.0M
$250.0M
$260.0M
$244.0M
$265.0M
$279.0M
$284.0M
$268.0M
$308.0M
$342.0M
Operating Expenses
$196.0M
$191.0M
$212.0M
$219.0M
$106.0M
$225.0M
$232.0M
$243.0M
$267.0M
$273.0M
$270.0M
$271.0M
Operating Profit
$35.0M
$15.0M
$30.0M
$32.0M
$154.0M
$19.0M
$32.0M
$36.0M
$17.0M
−$5.0M
$38.0M
$72.0M
Operating Margin
15.1%
7.4%
12.6%
12.6%
59.1%
7.9%
12.2%
12.8%
6.1%
-1.7%
12.3%
20.9%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$40.0M
$21.0M
$37.0M
$39.0M
$161.0M
$28.0M
$40.0M
$45.0M
$26.0M
$4.0M
$46.0M
$80.0M
Tax rate (%)
-15.3%
21.2%
10.2%
15.6%
10.8%
31.6%
33.7%
-61.0%
-939.4%
8.6%
32.2%
33.5%
Net Profit
$46.0M
$17.0M
$33.0M
$33.0M
$144.0M
$19.0M
$27.0M
$72.0M
$274.0M
$4.0M
$32.0M
$54.0M
EPS
$0.28
$0.10
$0.20
$0.20
$0.86
$0.11
$0.16
$0.42
$1.60
$0.02
$0.18
$0.31
Over the 10 years reported for ACADIA Pharmaceuticals Inc., cash stood at $178.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.83 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$561.0M
$385.0M
$540.0M
$783.0M
$783.0M
$700.0M
$588.0M
$749.0M
$1.2B
$1.6B
Current Assets
$548.0M
$373.0M
$526.0M
$760.0M
$718.0M
$618.0M
$508.0M
$616.0M
$938.0M
$1.1B
Cash
$164.0M
$69.0M
$135.0M
$190.0M
$326.0M
$147.0M
$115.0M
$189.0M
$320.0M
$178.0M
Inventory
$4.0M
$5.0M
$4.0M
$6.0M
$10.0M
$8.0M
$7.0M
$36.0M
$22.0M
$35.0M
Receivables
$7.0M
$18.0M
$28.0M
$38.0M
$50.0M
$65.0M
$63.0M
$102.0M
$105.0M
$148.0M
Fixed Assets
$3.0M
$3.0M
$3.0M
$13.0M
$56.0M
$66.0M
$62.0M
$56.0M
$51.0M
$55.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$368.0M
$274.0M
$344.0M
$515.0M
$313.0M
$377.0M
$315.0M
$256.0M
$445.0M
$650.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$43.0M
$49.0M
$61.0M
$84.0M
$156.0M
$159.0M
$187.0M
$317.0M
$455.0M
$337.0M
Current Liabilities
$43.0M
$49.0M
$60.0M
$75.0M
$106.0M
$96.0M
$126.0M
$254.0M
$395.0M
$277.0M
Borrowings
$0
$0
$0
$10.0M
$50.0M
$64.0M
$62.0M
$57.0M
$52.0M
$52.0M
Other Liabilities
$43.0M
$49.0M
$61.0M
$74.0M
$106.0M
$95.0M
$125.0M
$260.0M
$403.0M
$285.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$518.0M
$335.0M
$479.0M
$699.0M
$627.0M
$541.0M
$400.0M
$432.0M
$733.0M
$1.2B
For ACADIA Pharmaceuticals Inc., operating cash flow was positive in 3 of 10 reported years; free cash flow in the latest year was $105.0M; free cash flow was positive in 2 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$210.0M
−$218.0M
−$167.0M
−$151.0M
−$136.0M
−$126.0M
−$114.0M
$17.0M
$158.0M
$110.0M
Investing Cash Flow
−$271.0M
$185.0M
−$74.0M
−$167.0M
$185.0M
−$72.0M
$73.0M
−$8.0M
−$31.0M
−$307.0M
Financing Cash Flow
$15.0M
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Cash Flow
$61.0M
−$94.0M
$68.0M
$55.0M
$137.0M
−$179.0M
−$33.0M
$74.0M
$134.0M
−$142.0M
Free Cash Flow
−$220.0M
−$219.0M
−$170.0M
−$152.0M
−$144.0M
−$127.0M
−$114.0M
−$23.0M
$157.0M
$105.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.23
EV / EBITDA
19.31
FCF Yield
3.54%
Quick Ratio
3.70
Interest Coverage
—
Return 1Y
-20.69%
Return 3Y
-19.18%
Return 5Y
-12.30%
ACADIA Pharmaceuticals Inc. (ACAD) financials — frequently asked questions
What is ACADIA Pharmaceuticals Inc.'s annual revenue?
ACADIA Pharmaceuticals Inc. (ACAD) reported annual revenue of $1.1B in its most recent fiscal year.
What is ACADIA Pharmaceuticals Inc.'s net profit?
ACADIA Pharmaceuticals Inc. (ACAD) reported net profit of $391.0M in its most recent fiscal year.
What is ACAD EV/EBITDA?
ACADIA Pharmaceuticals Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 19.31.
Revenue and earnings of other Biotechnology stocks